Drugs / Flu-ATG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01145976 | Mar 2010 → Feb 2015 | aplastic anemia | Cooperative Study Group A for Hematology | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu-ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01145976 ↗ |
| Known as | Fludarabine | “Fludarabine” NCT01145976 ↗ |
| Route | Intravenous | “Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2)” NCT01145976 ↗ |